Literature DB >> 22268620

Multi-centre evaluation of a phenotypic extended spectrum β-lactamase detection guideline in the routine setting.

T N Platteel1, J W Cohen Stuart2, A J de Neeling3, G M Voets2, J Scharringa2, N van de Sande3, A C Fluit2, M J M Bonten2, M A Leverstein-van Hall4.   

Abstract

This study aimed to evaluate the routine setting performance of a guideline for phenotypic detection of extended spectrum β-lactamases (ESBLs) in Enterobacteriaceae, recommending ESBL confirmation with Etest or combination disc for isolates with a positive ESBL screen test (i.e. cefotaxime and/or ceftazidime MIC >1 mg/L or an automated system ESBL warning). Twenty laboratories submitted 443 Enterobacteriaceae with a positive ESBL screen test and their confirmation test result (74%Escherichia coli, 12%Enterobacter cloacae, 8%Klebsiella pneumoniae, 3%Proteus mirabilis, 2%Klebsiella oxytoca). Presence of ESBL genes was used as reference test. Accuracy of local phenotypic ESBL detection was 88%. The positive predictive value (PPV) of local screen tests was 70%, and differed per method (Vitek-2: 69%, Phoenix: 68%, disc diffusion: 92%), and species (95%K. pneumoniae-27%K. oxytoca). A low PPV (3%) was observed for isolates with automated system alarm but third-generation cephalosporin MICs <2 mg/L. Local ESBL confirmation had a PPV and negative predictive value (NPV) of 93% and 90%, respectively. Compared with centrally performed confirmation tests, 7% of local tests were misinterpreted. Combination disc was more specific than Etest (91% versus 61%). Confirmation tests were not reliable for P. mirabilis and K. oxytoca (PPV 33% and 38%, respectively, although NPVs were 100%). In conclusion, performance of Etests could be enhanced by education of technicians to improve their interpretation, by genotypic ESBL confirmation of P. mirabilis and K. oxytoca isolates with positive phenotypic ESBL confirmation, and by interpreting isolates with a positive ESBL alarm but an MIC <2 mg/L for cefotaxime and ceftazidime as ESBL-negative.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22268620     DOI: 10.1111/j.1469-0691.2011.03739.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

1.  High prevalence of antimicrobial resistance among common bacterial isolates in a tertiary healthcare facility in Rwanda.

Authors:  Cyprien Ntirenganya; Olivier Manzi; Claude Mambo Muvunyi; Onyema Ogbuagu
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

2.  Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.

Authors:  Florine N J Frakking; Wouter C Rottier; J Wendelien Dorigo-Zetsma; Jarne M van Hattem; Babette C van Hees; Jan A J W Kluytmans; Suzanne P M Lutgens; Jan M Prins; Steven F T Thijsen; Annelies Verbon; Bart J M Vlaminckx; James W Cohen Stuart; Maurine A Leverstein-van Hall; Marc J M Bonten
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

3.  Evaluation of the Oxoid Brilliance™ CRE Agar for the detection of carbapenemase-producing Enterobacteriaceae.

Authors:  J Cohen Stuart; G Voets; W Rottier; S Voskuil; J Scharringa; K Van Dijk; A C Fluit; M Leverstein-Van Hall
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-02       Impact factor: 3.267

4.  Differences in the antibiotic susceptibility of human Escherichia coli with poultry-associated and non-poultry-associated extended-spectrum beta-lactamases.

Authors:  T N Platteel; M A Leverstein-Van Hall; J W Cohen Stuart; G M Voets; M P van den Munckhof; J Scharringa; N van de Sande; A C Fluit; M J M Bonten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-22       Impact factor: 3.267

5.  Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

Authors:  Pranita D Tamma; Virginia M Pierce; Sara E Cosgrove; Ebbing Lautenbach; Anthony Harris; Divya Rayapati; Jennifer H Han
Journal:  Open Forum Infect Dis       Date:  2018-06-08       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.